Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) insider Christopher John Morl sold 15,034 shares of the firm’s stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $51.38, for a total value of $772,446.92.
NASDAQ:DCPH traded down $0.47 during mid-day trading on Thursday, hitting $51.38. 412,323 shares of the stock traded hands, compared to its average volume of 412,711. The business’s 50-day moving average price is $44.24 and its 200 day moving average price is $32.15. The company has a market cap of $2.62 billion, a PE ratio of -18.22 and a beta of 1.94. Deciphera Pharmaceuticals Inc has a 12-month low of $19.69 and a 12-month high of $52.35.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its earnings results on Monday, November 4th. The company reported ($1.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by ($0.09). As a group, sell-side analysts predict that Deciphera Pharmaceuticals Inc will post -4.25 EPS for the current year.
Institutional investors have recently added to or reduced their stakes in the company. Bank of Montreal Can purchased a new stake in shares of Deciphera Pharmaceuticals in the second quarter worth $28,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Deciphera Pharmaceuticals by 162.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,737 shares of the company’s stock worth $59,000 after buying an additional 1,074 shares in the last quarter. Tower Research Capital LLC TRC bought a new position in Deciphera Pharmaceuticals in the 2nd quarter worth about $64,000. JPMorgan Chase & Co. increased its stake in Deciphera Pharmaceuticals by 89.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,057 shares of the company’s stock worth $95,000 after acquiring an additional 1,913 shares during the last quarter. Finally, Morgan Stanley increased its stake in Deciphera Pharmaceuticals by 214.8% in the 2nd quarter. Morgan Stanley now owns 7,864 shares of the company’s stock worth $177,000 after acquiring an additional 5,366 shares during the last quarter. 69.45% of the stock is currently owned by hedge funds and other institutional investors.
A number of analysts recently issued reports on the stock. Piper Jaffray Companies set a $55.00 price objective on shares of Deciphera Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, September 30th. BidaskClub raised Deciphera Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday. SunTrust Banks boosted their target price on Deciphera Pharmaceuticals to $60.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. HC Wainwright began coverage on Deciphera Pharmaceuticals in a research report on Thursday, October 3rd. They set a “buy” rating and a $60.00 price target on the stock. Finally, JMP Securities increased their price target on Deciphera Pharmaceuticals from $45.00 to $54.00 and gave the stock a “market outperform” rating in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $49.31.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.
Featured Story: Buyback For Investors Defined
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.